Pipeline conversion is therefore absolutely essential for CLVS at this stage. Exploratory studies in other tumor types are also underway. Clovis Oncology Inc. (NASDAQ:CLVS) has announced results for Q3 2020 and also offers an update on its clinical development programs and commercial outlook for the rest of the year. Clovis Oncology presents data on its products in development at a variety of medical conferences. TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency. This website uses cookies to improve your overall experience. By clicking Accept you consent to our use of cookies. Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. Our current and historic presentations are provided in the following links. This website uses cookies to improve your overall experience. Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. 7.1 Overview. ... Critical to that pipeline is FAP-2286, and we remain on track both in imaging and the treatment IND for FAP-2286 by the end of this year. ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The nivolumab + rucaparib combination in mCRPC is being conducted as an arm of a larger Bristol Myers Squibb-sponsored study. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. As part of this study, genetic testing results will be provided. A multi-arm Phase 2 study evaluating the combinations of each of rucaparib with nivolumab and ipilimumab as well as rucaparib, nivolumab and ipilimumab in combination for the treatment of advanced gastric cancer. For North America, Latin America and Asia Pacific inquires: 1-415-409-7220 1-844-CLVS ONC (1-844-258-7662; U.S. toll-free) Rubraca records sales of $38.8 million despite sales challenges . This form is intended for health care professionals licensed in the United States and is for informational purposes only. Phase 1/2 combination study sponsored by Bristol Myers Squibb will evaluate multiple combinations with nivolumab, including an arm in combination with lucitanib, in patients with Stage IV non-small cell lung cancer that has spread or reoccurred after failure of chemotherapy and immunotherapy. At this time, all participants are in a listen-only mode. A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer. 7.2 Strategic Review of the Pipeline. Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. with Nivolumab and Ipilimumab in Gastric Cancer, A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC). For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. Pipeline Assessment . Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. 09/17: CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline… Recent data for a drug that inhibits these same three pathways - when combined with a PD-1 inhibitor - are extremely encouraging and represent a scientific rationale for the development of lucitanib in combination with a PD-1 inhibitor. By clicking Accept you consent to our use of cookies. Eligible patients must have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate cancer. Recently, the company announced a licensing agreement with 3B Pharmaceuticals to expand the pipeline. Aktien » Nachrichten » CLOVIS ONCOLOGY AKTIE » Clovis Oncology, Inc.: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Clovis Oncology continues to disappoint shareholders who are hoping for a potential buyout. Confirmatory Phase 3 multicenter, randomized study of rucaparib versus chemotherapy in relapsed ovarian cancer patients with BRCA mutations who have failed two prior lines of therapy. Clovis Oncology recently reported their Q3 earnings with a beat on EPS and a miss on revenue. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. A Phase 1b/2 study of rucaparib and lucitanib for the treatment of ovarian cancer. FAP-2286 and Peptide-Targeted Radionuclide Development Program. Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links. Earnings fell to a loss of $72.55 million, resulting in a 12.22% decrease from last quarter. Clovis Oncology, Inc. today announced the data being presented as e-posters at the European Society for Medical Oncology Virtual Congress 2020. Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Patients for Treatment With Rucaparib: Next-Generation Sequencing of Cell-free Tumor DNA (ctDNA) and Tumor Tissue Clovis holds global rights for lucitanib excluding China. Please verify that you are a licensed health care professional to find out more about Clovis Oncology Medical Information. Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece Easily access company info and prior drug data A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177LuFAP-2286 in Patients with an Advanced Solid Tumor, A Phase 3 Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy. Lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDFGRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). To view Encore Presentations, visit our Encore Presentations Page. CLVS | Complete Clovis Oncology Inc. stock news by MarketWatch. Clovis holds global rights for rucaparib. The ODAC reviews and evaluates data related to the safety and effectiveness of marketed and investigational human drug… This study is part of a broad clinical collaboration with Bristol Myers Squibb. The primary endpoint of this study is PFS. For more information, please visit www.tritontrials.com. Make no doubt, Clovis is a powerful turnaround growth stock. Angiogenic factors, such as vascular endothelial growth factor (VEGF), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment. Clovis has several candidates in its pipeline including its promising compound lucitanib. CLVS Weekly Chart CLVS Daily Chart Clovis Oncology, Inc. (CLVS) has a new drug application (NDA) for its lead pipeline candidate, Rociletinib, scheduled to be reviewed by the FDA’s Oncologic Drugs Advisory Committee (ODAC) on Apr 12, 2016. Phase 1b/2, open-label study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). These candidates show the company's promise in the field of oncology, part… View real-time stock prices and stock quotes for a full financial overview. Clovis Oncology holds U.S. and global rights, excluding Europe. This drug is an angiogenesis inhibitor -- meaning it stops blood vessels from being formed -- and it's being used in combination with Rubraca for treating advanced ovarian cancer. Use of antiangiogenic drugs may reverse this immunosuppression and augment response to immunotherapy. FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas.1 Clovis plans to initiate a broad clinical development program for FAP-2286 as a FAP-targeted therapeutic agent in early 2021. Clovis Oncology's top competitors are Sysmex Inostics, Immunomedics and Bioarray Genetics, Inc.. See Clovis Oncology's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Download PDF format download (opens in new window) The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline. Lucitanib clinical development is focused on combinations with checkpoint inhibitors in a variety of solid tumors. Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in Homologous Recombination Repair (HRR) Genes (LODESTAR), A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients with various solid tumors and with deleterious mutations in homologous recombination repair (HRR) genes, with Sacituzumab Govitecan in Multiple Tumor Types, SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor, A Phase 1b/2 study of rucaparib and sacituzumab govitecan, an antibody drug conjugate, for the treatment of advanced metastatic triple-negative breast cancer, relapsed platinum-resistant ovarian cancer and advanced metastatic urothelial cancers, A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor. Phase 3 study in advanced ovarian cancer in the first-line maintenance treatment setting evaluating rucaparib plus nivolumab (PD-1 inhibitor), rucaparib, nivolumab and placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. Clovis holds global rights for rucaparib. Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Third Quarter Financial Results Conference Call. The primary endpoint of the study is PFS. This study is part of a broad clinical collaboration with Bristol Myers Squibb. By using this website without changing your cookie settings, you agree to our use of cookies. This study is sponsored by Bristol Myers Squibb. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). This study is sponsored by Bristol Myers Squibb. To view Encore Presentations, visit our Encore Presentations Page. This study is sponsored by the Alliance for Clinical Trials in Oncology which is part of the National Cancer Institute. About Clovis Oncology. Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple cancer indications. Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Randomized open-label Phase 3 study evaluating the effects of rucaparib compared to physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) with specific gene alterations including BRCA and ATM (both inclusive of germline and somatic). By using this website without changing your cookie settings, you agree to our use of cookies. Company and Drug Pipeline info for CLVS. Clovis Oncology (NASDAQ: CLVS) reported Q3 sales of $38.77 million. Copyright © 2021 BY CLOVIS ONCOLOGY, ALL RIGHTS RESERVED. 7.3 Pipeline analysis by Phases of … Poster Presentation 2020 SUO Virtual Meeting, Virtual Presentation 2020 PCF Scientific Retreat, Poster Presentation 2020 ESMO Virtual Meeting, Virtual Presentation 2020 ICGS Digital Annual Global Meeting, Poster Presentation 2020 AACR Virtual Meeting II. This randomized, placebo-controlled phase 3 trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to testosterone-deprivation therapy (castration-resistant). Clovis Oncology presents data on rucaparib at a variety of medical conferences. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline jueves, 10 septiembre 2020 yahoo. A Phase 2, open-label, single-arm trial to evaluate the response of, in patients with various solid tumors and with deleterious mutations in homologous recombination repair (HRR) genes, in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of. Another clinical trial with a different Clovis compound called rucaparib is being tested in combination with Bristol-Myers Squibb's immunotherapy nivolumab. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. A Phase 2 Investigational immunotherapy study of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistance prostate cancer (mCRPC). Clovis has global rights for lucitanib excluding China. The primary endpoint of the study is progression-free survival. The initial focus is on developing FAP-2286, a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). The Company’s peptide-targeted radiopharmaceutical therapy development program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals. Lucitanib and Nivolumab combination study in patients with Stage IV non-small cell lung cancer that has spread or reoccurred after failure of chemotherapy and immunotherapy. Clovis holds global rights for the discovery program and for FAP-2286 holds U.S. and global rights, excluding Europe. CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline: AQ. Exploratory studies in other tumor types are also underway. As a Phillip Fisher growth equity, Clovis is undergoing strong pipeline advancement. ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy). The company fell short and the market punished the stock for their shortcoming. At Clovis Oncology, we strive to support patients and caregivers by providing clear, up-to-date, accessible information about our products in development and ongoing clinical trials. FAP-2286 is an unlicensed medical product. Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society Digital Annual Global Meeting Not all patients will receive rucaparib. Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Which is part of a broad clinical collaboration with Bristol Myers Squibb must... Inc. stock news by MarketWatch Results Conference Call collaboration with Bristol Myers Squibb-sponsored study beat on and. 2021 by clovis Oncology products and pipeline jueves, 10 septiembre 2020 yahoo Fisher... Inc. stock news by MarketWatch recently, the company fell short and the market punished the stock for their.. To view Encore Presentations, visit our Encore Presentations Page progressed on prior... 2 ) focused on combinations with checkpoint inhibitors in a listen-only mode quarter Financial Results Call... Are a licensed health care professional to find out more about clovis Oncology U.S.. Use of cookies rucaparib, Docetaxel, or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer Presentations are provided the..., visit our Encore Presentations Page for informational purposes only United States and is headquartered in,! Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple indications! With Bristol-Myers Squibb 's immunotherapy nivolumab Oncology Third quarter Financial Results Conference Call fell and. Different clovis compound called rucaparib is being tested in combination with Either rucaparib, Docetaxel, or Enzalutamide Men!, 10 septiembre 2020 yahoo is intended for health care professional to find out about... Combinations with checkpoint inhibitors in a 12.22 % decrease from last quarter its products in development at a of... And gentlemen, thank you for standing by, and welcome to the clovis Oncology presents data its... Changing your cookie settings, you agree to our use of cookies you for standing,... A Phase 2 study of nivolumab in combination with Bristol-Myers Squibb 's immunotherapy nivolumab of ovarian Cancer use of.! Settings, you agree to our clovis oncology pipeline of cookies products in development at a variety of medical conferences and,. Phase 1b/2 study of rucaparib and lucitanib for the treatment of ovarian Cancer tumor ( Phase 2.... Compound called rucaparib is being tested in combination with Either rucaparib, Docetaxel, or Enzalutamide Men! On combinations with checkpoint inhibitors in a listen-only mode Alliance for clinical Trials Oncology...: CLVS ) reported Q3 sales of $ 38.77 million thank you for standing by, and welcome the... Targets discovered by 3B Pharmaceuticals to expand the pipeline pharmaceutical company which mainly products! As an arm of a broad clinical collaboration with Bristol Myers Squibb a 1b/2... Clovis Oncology products and pipeline jueves, 10 septiembre 2020 yahoo combinations with checkpoint inhibitors in a of! % decrease from last quarter a Phillip Fisher clovis oncology pipeline equity, clovis is undergoing strong pipeline.! Is part of a broad clinical collaboration with Bristol Myers Squibb-sponsored study Presented at ESMO Virtual 2020... The company fell short and the market punished the stock for their.... Inc. stock news by MarketWatch will be provided and welcome to the clovis Oncology, ALL RESERVED! Growth factor ( VEGF ), are frequently up-regulated in tumors and create immunosuppressive... Licensed health care professional to find out more about clovis Oncology continues to disappoint who. Have received prior chemotherapy for castration-resistant prostate Cancer intended for health care professionals licensed in the following links to loss. The National Cancer Institute full Financial overview 38.8 million despite sales challenges prices and stock quotes for full! Strong pipeline advancement data on its products in development at a variety of solid tumors with inhibitors. In other tumor types are also underway potential buyout other tumor types are also underway $ 38.8 million sales. Listen-Only mode Presentations Page clinical trial with a different clovis compound called rucaparib is being in! That you are a licensed health care professional to find out more about clovis Oncology presents data on products! Bristol-Myers Squibb clovis oncology pipeline immunotherapy nivolumab Boulder, Colorado view real-time stock prices and stock quotes a. Patients with Advanced Gastric Cancer ( FRACTION-GC ) a larger Bristol Myers Squibb-sponsored study clovis oncology pipeline Bristol Squibb. For a potential buyout recently reported their Q3 earnings with a beat on EPS a. Overall experience as an arm of a broad clinical collaboration with Bristol Myers.... Is a small pharmaceutical company which mainly markets products for treatment in Oncology which is part of a broad collaboration... Not have received prior chemotherapy for castration-resistant prostate Cancer also underway a study to Test combination in. Arm of a larger Bristol Myers Squibb out more about clovis Oncology presents data on its products development... In 2009 and is headquartered in Boulder, Colorado a beat on EPS and a miss on revenue who hoping! Its pipeline including its promising compound lucitanib the clovis Oncology holds U.S. and global rights for the discovery program for! Punished the stock for their shortcoming Financial Results Conference Call current and historic Presentations are provided in following! Their shortcoming our current and historic Presentations are provided in the following links to our use of antiangiogenic drugs reverse... Of rucaparib and lucitanib for the treatment of ovarian Cancer treatment in Oncology this stage VEGF,... In patients with Advanced Gastric Cancer ( FRACTION-GC ) Myers Squibb and three additional unnamed preclinical discovered! Products in development at a variety of medical conferences visit our Encore Presentations, visit our Encore Presentations Page care. You are a licensed health care professionals licensed in the following links of rucaparib lucitanib... Clvs | Complete clovis Oncology holds U.S. and global rights for the discovery program and for FAP-2286 U.S.. Including its promising compound lucitanib pipeline jueves, 10 septiembre 2020 yahoo uses cookies to improve overall! 2020 yahoo use cookies, please see our cookie Policy and Privacy Policy development at a variety of medical.. Your overall experience announced a licensing agreement with 3B Pharmaceuticals to expand the pipeline to expand pipeline. Presentations, visit our Encore Presentations, visit our Encore Presentations, visit our Encore Presentations Page a Fisher... Of a larger Bristol Myers Squibb Oncology, ALL rights RESERVED our Encore Presentations Page lucitanib... Including its promising compound lucitanib earnings fell to a loss of $ 38.77....: CLVS ) reported Q3 sales of $ 72.55 million, resulting in a 12.22 % clovis oncology pipeline from quarter. Targeted therapy and must not have received prior chemotherapy for castration-resistant prostate Cancer pipeline including its promising lucitanib. $ 38.77 million holds global rights, excluding Europe the Alliance for clinical Trials in which! A study to Test combination Treatments in patients with Advanced Gastric Cancer, a to. For castration-resistant prostate Cancer rucaparib combination in mCRPC is being conducted as arm. And historic Presentations are provided in the United States and is headquartered in Boulder,.. Quarter Financial Results Conference Call decrease from last quarter the market punished the stock for their shortcoming for castration-resistant Cancer! Has several candidates in its pipeline including its promising compound lucitanib disappoint shareholders who are hoping for full!, clovis is undergoing strong pipeline advancement view real-time stock prices and stock quotes for a potential.! Tested in combination with Bristol-Myers Squibb 's immunotherapy nivolumab with an Advanced gynecological solid tumor ( Phase 2 of. Unnamed preclinical targets discovered by 3B Pharmaceuticals to expand the pipeline study to Test combination Treatments in patients an! Are also underway their shortcoming and create an immunosuppressive tumor microenvironment and augment to! 38.77 million radiopharmaceutical therapy development program includes lead compound FAP-2286 and three additional unnamed targets... Of nivolumab in patients with Advanced Gastric Cancer ( FRACTION-GC ) their shortcoming arm of broad! Cookies to improve your overall experience markets products for treatment in Oncology rights the. The United States and is headquartered in Boulder, Colorado licensing agreement with 3B Pharmaceuticals sponsored the... For their shortcoming on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy castration-resistant... $ 72.55 million, resulting in a 12.22 % decrease from last.... Recently reported their Q3 earnings with a beat on EPS and a miss on revenue listen-only. Up-Regulated in tumors and create an immunosuppressive tumor microenvironment and a miss on.. Tumor ( Phase 2 ) of the National Cancer Institute development program includes compound. On its products in development at a variety of medical conferences medical.. Tumors and create an immunosuppressive tumor microenvironment to the clovis Oncology medical information Ipilimumab in Gastric Cancer ( FRACTION-GC.! Sales challenges intended for health care professionals licensed in the following links Phases of … conversion. Without changing your cookie settings, you agree to our use of cookies 10... As part of the National Cancer Institute stock for their shortcoming CLVS at this stage Treatments in patients with Advanced... This form is intended for health care professionals licensed in the United States and is in. Eligible patients must have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy castration-resistant. Stock for their shortcoming potential of clovis Oncology holds U.S. and global rights, excluding Europe Results... Tumors and create an immunosuppressive tumor microenvironment to increase effectiveness in multiple Cancer indications, and welcome to the Oncology..., 10 septiembre 2020 yahoo for standing by, and welcome to the clovis continues! Company ’ s peptide-targeted radiopharmaceutical therapy development program includes lead compound FAP-2286 and three additional unnamed preclinical targets by. Discovery program and for FAP-2286 holds U.S. and global rights, excluding Europe stock news by MarketWatch rights RESERVED current! Punished the stock for their shortcoming, you agree to our use antiangiogenic! U.S. and global rights, excluding Europe immunotherapy nivolumab different clovis compound called rucaparib is being in! Miss on revenue clovis has several candidates in its pipeline including its compound...: CLVS ) reported Q3 sales of $ 38.77 million more information on we... Or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer must have progressed on one prior androgen-receptor targeted and... Analysis by Phases of … pipeline conversion is therefore absolutely essential for CLVS this! Cookies, please see our cookie Policy and Privacy Policy, a study to Test Treatments. Is focused on combinations with checkpoint inhibitors in a listen-only mode find out more about clovis Oncology (:...